REZUROCK is surely an inhibitor of UGT1A1. Coadministration of REZUROCK with a UGT1A1 substrate diminished plasma concentrations from the glucuronide metabolite, which can increase the risk of adverse reactions linked to sensitive substrates of UGT1A1Modern innovations in genetic engineering have allotted us a chance to change cells, most notably,